seen from Canada
seen from Malaysia
seen from Germany
seen from Thailand
seen from United States
seen from China
seen from United States
seen from Malaysia
seen from Malaysia
seen from United States
seen from United States
seen from China
seen from United Kingdom
seen from Philippines
seen from United Kingdom
seen from Philippines
seen from Canada
seen from Malaysia
seen from United States
seen from United Kingdom
Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a positive opinion for the approval of Vizimpro (dacomitinib) developed by Pfizer, Inc. for the treatment of lung cancer. Pfizer is eyeing approval of Vizimpro (45 mg) in Europe for the first-line treatment of metastatic non-small cell lung cancer …
